Distant metastases in terminal head and neck cancer patients.
With improved control of cancer above the clavicles, distant metastases (DM) are frequently more seen and are becoming a more common cause of morbidity and mortality. The present study defined the incidence of distant metastases in a cohort of terminal head and neck cancer patients (HNCP) and compared it to current reported data. The incidence of distant metastases in relation to the primary tumour was evaluated and their impact on survival was assessed. A retrospective survey of patient charts was made, based on the hospice database and original referring hospital charts. Data of 59 patients admitted to the hospice were evaluated. The incidence and location of locoregional and distant disease were studied and effects on survival analyzed. The overall survival from diagnosis to demise was 42.7 months. Thyroid cancer was seen in 20.3 per cent of cases and squamous cell cancer was seen in 59.3 per cent. Distant metastases were found in 83 per cent and 48.6 per cent of patients respectively. Laryngeal cancer patients had a 54.5 per cent incidence of distant metastases. Locoregional disease was seen in 47 per cent of cases and 35.7 per cent of them had distant metastases while a 64.3 per cent incidence of distant metastases was found in cases without locoregional disease. Mean survival was 47.3 months with distant metastases vs 36.5 months without metastases. The difference was not statistically significant. The incidence of distant metastases in squamous cell cancer in terminal HNCP was 48.6 per cent. This is the highest reported incidence of metastases in a clinical series. Patients without locoregional disease had almost a two-fold incidence of metastases. Survival was not affected by metastases in this series.
Talmi
Y P
YP
Department of Otolaryngology, Head and Neck Surgery, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Cotlear
D
D
Waller
A
A
Horowitz
Z
Z
Adunski
A
A
Roth
Y
Y
Kronenberg
J
J
D000368:Aged; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary*; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000556:secondary*; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology*; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000401:mortality / Q000556:secondary; D010255:Paranasal Sinus Neoplasms / Q000401:mortality / Q000556:secondary; D012189:Retrospective Studies; D015996:Survival Rate